Long-term pasireotide-LAR treatment in the personalized therapy of patients with complex acromegaly: a collection of clinical experiences

Pasireotide-LAR is recommended as a second-line treatment for patients with acromegaly. Although the effects of pasireotide-LAR have been well characterized in clinical studies, real-practice evidence is scant, especially in the long term and within the individualization of therapy in patients with...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Drugs in Context 2024-05, Vol.13, p.1-9
Hauptverfasser:	Chiloiro, Sabrina, Appetecchia, Marialuisa, Bianchi, Antonio, Costa, Denise, De Acetis, Christine, Gargiulo, Patrizia, Giampietro, Antonella, Isidori, Andrea M, Jaffrain-Rea, Marie-Lise, Passeri, Marina, Pigliaru, Francesca, Poggi, Maurizio, De Marinis, Laura
Format:	Artikel
Sprache:	eng
Schlagworte:	acromegaly Case Series diabetes mellitus growth hormone igf1 pasireotide-lar somatotropinoma
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!